{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T14:02:26Z","timestamp":1770732146323,"version":"3.49.0"},"reference-count":42,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2019s Horizon Europe research and innovation program","award":["101136957"],"award-info":[{"award-number":["101136957"]}]},{"name":"Innovative Health Initiative Joint Undertaking","award":["101132356"],"award-info":[{"award-number":["101132356"]}]},{"name":"European Union\u2019s Horizon Europe Research and Innovation Program, COCIR, EFPIA, EuropaBio, MedTechEurope, and Vaccines Europe"},{"name":"EU Joint Program\u2014Neurodegenerative Disease Research","award":["JPND2023-1822-085"],"award-info":[{"award-number":["JPND2023-1822-085"]}]},{"name":"National Research Development and Innovation Office, Hungary","award":["2024-1.2.2-ERA_NET-2024-00013"],"award-info":[{"award-number":["2024-1.2.2-ERA_NET-2024-00013"]}]},{"name":"National Research Development and Innovation Office, Hungary","award":["2020-1.1.2-PIACI-KFI-2021-00233"],"award-info":[{"award-number":["2020-1.1.2-PIACI-KFI-2021-00233"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Reliable and disease-specific blood biomarkers are critically needed for Alzheimer\u2019s disease (AD), particularly in early stages when interventions are most effective. Although phosphorylated tau and neurofilament light chain (NfL) are widely used, their diagnostic specificity has been reported to decrease in elderly populations with multimorbidities. Syndecan-3 (SDC3), a heparan sulfate proteoglycan implicated in amyloid and tau aggregation, has recently emerged as a mechanistically relevant biomarker candidate. In this clinically realistic cohort study, we examined 46 participants, including 23 clinically diagnosed AD patients and 23 age-matched non-AD individuals with psychiatric and\/or metabolic comorbidities. SDC3 expression was quantified in peripheral blood mononuclear cells (PBMCs), while soluble SDC3 and NfL were measured in plasma. Both PBMC-expressed and plasma SDC3 levels were elevated in AD compared with non-AD participants and showed a strong intercorrelation, whereas plasma NfL was likewise increased in AD. Individually, PBMC-SDC3, plasma SDC3, and NfL demonstrated moderate discriminatory performance. However, multivariable models integrating SDC3 (PBMC or plasma), NfL, and age achieved substantially improved discrimination (AUC &gt; 0.8). SDC3 did not correlate with NfL, consistent with a biological signal distinct from neuroaxonal injury and reflective of peripheral immune\u2013metabolic remodeling. Together, these findings identify SDC3 as a blood-based biomarker associated with systemic immune remodeling that complements established neuronal markers in a clinically realistic AD versus non-AD comparison. While exploratory, this study supports further investigation of SDC3 within integrated, multi-domain biomarker strategies in larger and independent cohorts.<\/jats:p>","DOI":"10.3390\/ijms27031600","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:05:47Z","timestamp":1770372347000},"page":"1600","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peripheral Syndecan-3 and Neurofilament Light Chain as Complementary Blood Biomarkers for Alzheimer\u2019s Disease"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6294-5345","authenticated-orcid":false,"given":"Anett","family":"Hud\u00e1k","sequence":"first","affiliation":[{"name":"Pharmacoidea Ltd., H-6726 Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annam\u00e1ria","family":"Letoha","sequence":"additional","affiliation":[{"name":"Department of Medicine, Albert Szent-Gy\u00f6rgyi Clinical Center, Faculty of Medicine, University of Szeged, H-6720 Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6035-4009","authenticated-orcid":false,"given":"Tam\u00e1s","family":"Letoha","sequence":"additional","affiliation":[{"name":"Pharmacoidea Ltd., H-6726 Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102481","DOI":"10.1016\/j.arr.2024.102481","article-title":"Pathogenesis, diagnostics, and therapeutics for Alzheimer\u2019s disease: Breaking the memory barrier","volume":"101","author":"Kamatham","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Abdul Manap, A.S., Almadodi, R., Sultana, S., Sebastian, M.G., Kavani, K.S., Lyenouq, V.E., and Shankar, A. (2024). Alzheimer\u2019s disease: A review on the current trends of the effective diagnosis and therapeutics. Front. Aging Neurosci., 16.","DOI":"10.3389\/fnagi.2024.1429211"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: Mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100078","DOI":"10.1016\/j.neumar.2025.100078","article-title":"Blood biomarkers for clinical applications in Alzheimer\u2019s disease: A narrative review","volume":"2","author":"Li","year":"2025","journal-title":"NeuroMarkers"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: A critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.neuron.2024.02.017","article-title":"P-tau217 correlates with neurodegeneration in Alzheimer\u2019s disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy","volume":"112","author":"Zhang","year":"2024","journal-title":"Neuron"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Varela-Vidales, C.A., Martinez-Hernandez, A., Hernandez-Castellanos, E., and Delgado-Lara, D.L.C. (2025). P-tau217 as a Biomarker in Alzheimer\u2019s Disease: Applications in Latin American Populations. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146633"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.conb.2020.02.001","article-title":"Neurofilaments in disease: What do we know?","volume":"61","author":"Gordon","year":"2020","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e34720","DOI":"10.1016\/j.heliyon.2024.e34720","article-title":"Global research trends on the links between NfL and neurological disorders: A bibliometric analysis and review","volume":"10","author":"Song","year":"2024","journal-title":"Heliyon"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12035-019-01698-3","article-title":"Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders","volume":"57","author":"Alirezaei","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e70411","DOI":"10.1002\/alz.70411","article-title":"Multimorbidity patterns and blood biomarkers of Alzheimer\u2019s disease in community-dwelling cognitively unimpaired older adults","volume":"21","author":"Marengoni","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13195-025-01692-z","article-title":"The impact of kidney function on Alzheimer\u2019s disease blood biomarkers: Implications for predicting amyloid-beta positivity","volume":"17","author":"Arslan","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13195-024-01401-2","article-title":"The impact of kidney function on plasma neurofilament light and phospho-tau 181 in a community-based cohort: The Shanghai Aging Study","volume":"16","author":"Wu","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/s41467-025-57144-7","article-title":"Phosphorylated tau 181 and 217 are elevated in serum and muscle of patients with amyotrophic lateral sclerosis","volume":"16","author":"Scholle","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e70931","DOI":"10.1002\/alz.70931","article-title":"Enhancing diagnostic precision in Alzheimer\u2019s disease: Impact of comorbidities on blood biomarkers for clinical integration","volume":"21","author":"Daniilidou","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yang, K.L., Ma, Y., Ennis, G., Jonaitis, E., Rea Reyes, R.E., Johnson, S.C., Ashton, N.J., Blennow, K., Zetterberg, H., and Bendlin, B.B. (2025). Metabolic factors associated with plasma phosphorylated tau analytes used to detect Alzheimer\u2019s disease pathology. medRxiv.","DOI":"10.1101\/2025.07.27.25332280"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e14430","DOI":"10.1002\/alz.14430","article-title":"Influence of medical conditions on the diagnostic accuracy of plasma p-tau217 and p-tau217\/Abeta42","volume":"21","author":"Sewell","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_19","first-page":"e12358","article-title":"Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction","volume":"14","author":"Thanapornsangsuth","year":"2022","journal-title":"Alzheimers Dement."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e210287","DOI":"10.1212\/WNL.0000000000210287","article-title":"Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations","volume":"104","author":"Bornhorst","year":"2025","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"332ra344","DOI":"10.1126\/scitranslmed.aad3650","article-title":"Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-beta clearance and aggregation in Alzheimer\u2019s disease","volume":"8","author":"Liu","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hudak, A., Josvay, K., Domonkos, I., Letoha, A., Szilak, L., and Letoha, T. (2021). The Interplay of Apoes with Syndecans in Influencing Key Cellular Events of Amyloid Pathology. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22137070"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"16543","DOI":"10.1038\/s41598-019-53038-z","article-title":"Contribution of syndecans to cellular uptake and fibrillation of alpha-synuclein and tau","volume":"9","author":"Hudak","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/s41598-018-37476-9","article-title":"Contribution of syndecans to cellular internalization and fibrillation of amyloid-beta(1-42)","volume":"9","author":"Letoha","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hudak, A., Letoha, A., Vizler, C., and Letoha, T. (2022). Syndecan-3 as a Novel Biomarker in Alzheimer\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063407"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hudak, A., Letoha, A., and Letoha, T. (2025). Peripheral Leukocyte Syndecan-3 Is Elevated in Alzheimer\u2019s Disease: Evidence from a Human Study. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146587"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"eabg9922","DOI":"10.1126\/scitranslmed.abg9922","article-title":"Axonal marker neurofilament light predicts long-term outcomes and progressive neurodegeneration after traumatic brain injury","volume":"13","author":"Graham","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.14283\/jpad.2022.77","article-title":"Antihypertensive Agents and Incident Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis of Observational Studies","volume":"9","author":"Adesuyan","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_30","first-page":"e12060","article-title":"Antihypertensive medications ameliorate Alzheimer\u2019s disease pathology by slowing its propagation","volume":"6","author":"Affleck","year":"2020","journal-title":"Alzheimers Dement."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1253\/circj.CJ-12-1550","article-title":"Angiotensin-receptor blockers, hypertension and Alzheimer disease\u2015The entangled relationship","volume":"77","author":"Katayama","year":"2013","journal-title":"Circ. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.23736\/S0031-0808.18.03360-8","article-title":"High blood pressure, Alzheimer disease and antihypertensive treatment","volume":"60","author":"Marfany","year":"2018","journal-title":"Panminerva Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40263-015-0230-6","article-title":"Antihypertensive drugs, prevention of cognitive decline and dementia: A systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms","volume":"29","author":"Rouch","year":"2015","journal-title":"CNS Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/ajh\/hpu197","article-title":"Neuroprotective effects of angiotensin receptor blockers","volume":"28","author":"Villapol","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1179573520907397","DOI":"10.1177\/1179573520907397","article-title":"Current and Future Treatments in Alzheimer Disease: An Update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13024-025-00867-4","article-title":"Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: Current status and future directions","volume":"20","author":"Noh","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/alz.13450","article-title":"Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer\u2019s disease progression","volume":"20","author":"Pelkmans","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer\u2019s disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wang, Y.Y., Zhang, M., Chen, S.J., Miao, W., Wang, Z.X., Zhou, Y.J., Yu, S.Q., Sun, Z.W., Zhou, X., and Yu, X.F. (2025). Neuroinflammation-mediated YKL-40 correlates with tau pathology and predicts longitudinal cognitive impairment and brain atrophy in Alzheimer\u2019s disease, with hypertensive dependency. Front. Aging Neurosci., 17.","DOI":"10.3389\/fnagi.2025.1630022"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.14283\/jpad.2023.54","article-title":"Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer\u2019s Disease Continuum","volume":"10","author":"Bieger","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1600\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:09:23Z","timestamp":1770372563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27031600"],"URL":"https:\/\/doi.org\/10.3390\/ijms27031600","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]}}}